Peptides Are Having a Moment

April 8, 2026

In the first week of April 2026, something happened that doesn’t normally happen with injectable research compounds: everybody had an opinion.

STAT News ran a long piece on April 6 examining the “apparent contradiction” of Robert F. Kennedy Jr.—a man who built a political identity on vaccine skepticism—championing the return of unregulated peptides to compounding pharmacies. The framing was medical libertarianism: the government should stay out of what you inject into your body, unless it’s a vaccine. (STAT News, April 6)

Two days later, the American Council on Science and Health published “Miracle Molecules or Medical Mirage?”—a headline that tells you everything about the editorial posture before you read a word. (ACSH, April 8)

TIME ran a piece on anti-aging peptide shots trending on social media, with the obligatory montage of before-and-after TikToks and the obligatory concerned dermatologist. (TIME)

NPR’s Here & Now ran a segment on people buying “unregulated, injectable peptides from Chinese factories,” which is a sentence designed to make your mother call you. (WBUR/NPR, March 24)

NBC News went with the clean kill: “Peptides are surging in popularity. There’s little evidence that they work.” (NBC News)

And The New Yorker—The New Yorker—apparently said you’re crazy for using them, which prompted a rebuttal on Substack from The Peptide List that read like a man defending his honor at a cocktail party. (The Peptide List, Substack)

This is all happening while peptides hit 10.1 million monthly searches, GHK-Cu grew 1,016% year-over-year in search volume, and Eli Lilly got the fastest FDA approval of a new molecular entity since 2002 for an oral GLP-1 peptide called Foundayo—a drug that lets you take a weight-loss pill at any time of day without worrying about food or water. (Eli Lilly investor release, April 1)

Meanwhile, Peptide Sciences—a gray-market vendor that was reportedly doing $7.4 million a month in sales—shut down without warning on March 6, joining Science.bio in the growing list of vendors that just stopped existing one morning. (Lumalex Law analysis, March 13)

And a JAMA analysis found that roughly a quarter of tested peptide products contained undisclosed compounds—which is exactly the kind of finding that makes the NPR segment write itself.

So: the FDA is simultaneously approving peptide drugs at record speed and cracking down on peptide vendors at record volume. The HHS Secretary is announcing peptide reclassification on Joe Rogan’s podcast. The New Yorker and NBC are telling people peptides don’t work while 10 million monthly searchers appear to disagree. A systematic review of BPC-157 just confirmed there are 36 published studies and exactly zero controlled human trials. (PubMed: PMID 40756949) And Eli Lilly is projecting $16 billion in revenue from a single oral peptide by 2031.

There’s no grand unified theory for what all of this means. But peptides are everywhere right now—in the pharmacy, in the headlines, in the regulatory docket, in the Substack discourse, in the shuttered warehouses of vendors who bet wrong. If there’s an angle beyond “oh my, they’re everywhere,” it might be this: the peptide world is splitting into two tracks that are moving in opposite directions at the same time. The pharmaceutical track is accelerating—faster approvals, bigger trials, brand names, insurance coverage, $149-a-month pills. The self-experimentation track is getting squeezed—vendor shutdowns, warning letters, contamination studies, media scrutiny. Both tracks involve the same molecules. The question is whether they stay in the same conversation.

For now, they do. And that’s why everybody has an opinion this week.